FCM
PBLS

Farallon Capital Management’s Parabilis Medicines Inc PBLS Stock Holding History

Farallon Capital Management’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.8M Buy
+2,368,200
New +$65.4M 0.3% 37

Other funds holding PBLS

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Farallon Capital Management's PBLS Position: Q2 2026 in Review

Farallon Capital Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 2,368,200 shares worth $64.8M. The stake represents 0.3% of the portfolio and ranks #37 among its holdings.

63 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Farallon Capital Management held 2,368,200 shares of Parabilis Medicines Inc worth $64.8M as of Q2 2026.
  • Parabilis Medicines Inc was a new Farallon Capital Management position in Q2 2026.
  • Parabilis Medicines Inc made up 0.3% of Farallon Capital Management's portfolio in Q2 2026, its #37 holding.
  • 63 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.